MC1782A1 - Preparation pharmaceutique - Google Patents

Preparation pharmaceutique

Info

Publication number
MC1782A1
MC1782A1 MC861861A MC1861A MC1782A1 MC 1782 A1 MC1782 A1 MC 1782A1 MC 861861 A MC861861 A MC 861861A MC 1861 A MC1861 A MC 1861A MC 1782 A1 MC1782 A1 MC 1782A1
Authority
MC
Monaco
Prior art keywords
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
MC861861A
Other languages
English (en)
Inventor
Hargovindas Shas Navnit
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25175361&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MC1782(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MC1782A1 publication Critical patent/MC1782A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
MC861861A 1985-11-18 1986-11-17 Preparation pharmaceutique MC1782A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/799,229 US4892742A (en) 1985-11-18 1985-11-18 Controlled release compositions with zero order release

Publications (1)

Publication Number Publication Date
MC1782A1 true MC1782A1 (fr) 1987-09-02

Family

ID=25175361

Family Applications (1)

Application Number Title Priority Date Filing Date
MC861861A MC1782A1 (fr) 1985-11-18 1986-11-17 Preparation pharmaceutique

Country Status (16)

Country Link
US (1) US4892742A (fr)
EP (1) EP0224146B1 (fr)
JP (1) JPS62120316A (fr)
CN (1) CN86107734A (fr)
AU (1) AU594392B2 (fr)
CA (1) CA1289075C (fr)
DE (1) DE3685094D1 (fr)
DK (1) DK546886A (fr)
GR (1) GR862727B (fr)
HU (1) HU200683B (fr)
IL (1) IL80643A0 (fr)
MC (1) MC1782A1 (fr)
NZ (1) NZ218297A (fr)
PH (1) PH23292A (fr)
PT (1) PT83756B (fr)
ZA (1) ZA868249B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
SE8505034D0 (sv) * 1985-10-25 1985-10-25 Haessle Ab Kropp bestaende av en kerna med ett overdrag
EP0325086A3 (fr) * 1987-11-23 1990-10-31 Jago Research Ag Méthodes pour obtenir des systèmes thérapeutiques à libération contrôlée du médicament
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
GB8813064D0 (en) * 1988-06-02 1988-07-06 Euro Celtique Sa Controlled release dosage forms having defined water content
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IT1237904B (it) * 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
DE69107461T2 (de) * 1990-08-07 1995-06-22 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
EP0546593B1 (fr) * 1991-10-30 1997-09-03 Glaxo Group Limited Compositions multicouches contenant d'antagonistes de l'histamine ou de la sérotonine
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5160742A (en) * 1991-12-31 1992-11-03 Abbott Laboratories System for delivering an active substance for sustained release
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
WO1995022962A1 (fr) * 1994-02-23 1995-08-31 Bm Research A/S Composition a liberation regulee
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5482718A (en) * 1994-03-23 1996-01-09 Hoffmann-La Roche Inc. Colon-targeted delivery system
JPH08143450A (ja) * 1994-11-14 1996-06-04 Taiyo Yakuhin Kogyo Kk 徐放化製剤
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
FR2766707A1 (fr) * 1997-07-30 1999-02-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethyl-cellulose et/ou de l'ethylcellulose a titre d'agents desintegrants, et procede d'obtention
FR2766708B1 (fr) * 1997-07-30 2000-05-05 Galenix Dev Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
CA2327685C (fr) * 1998-04-03 2008-11-18 Bm Research A/S Composition a liberation lente
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
CZ303495B6 (cs) * 1998-11-02 2012-10-24 Elan Pharma International Limited Mnohocásticový modifikovane uvolnující prostredek a jeho použití, pevná orální dávkovací forma
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
US20090297597A1 (en) * 1998-11-02 2009-12-03 Gary Liversidge Modified Release Ticlopidine Compositions
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
PT1623703E (pt) 1999-10-29 2012-01-09 Euro Celtique Sa Formulações de hidrocodona de libertação controlada
AU767812B2 (en) * 2000-02-04 2003-11-27 Depomed, Inc. Shell-and-core dosage form approaching zero-order drug release
EP2283829A1 (fr) 2000-10-30 2011-02-16 Euro-Celtique S.A. Formulations d'hydrocodone à liberation lente
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
EP1429739A1 (fr) * 2001-09-21 2004-06-23 Egalet A/S Systeme de liberation a base de polymere
WO2003024430A1 (fr) * 2001-09-21 2003-03-27 Egalet A/S Systeme a liberation de polymere de morphine
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
EP1441703B1 (fr) * 2001-10-29 2018-01-03 Massachusetts Institute of Technology Forme pharmaceutique à profil de libération d'ordre zero élaborée en impression tridimensionnelle
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US20030118647A1 (en) * 2001-12-04 2003-06-26 Pawan Seth Extended release tablet of metformin
CA2470636A1 (fr) * 2001-12-20 2003-07-03 Pharmacia Corporation Formes dosifiees a liberation soutenue d'ordre zero et procede de production associe
EP1485078B1 (fr) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran pour le traitement du syndrôme du colon irritable
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20080220074A1 (en) * 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004041244A2 (fr) * 2002-10-30 2004-05-21 Pharmacia Corporation Comprimes oraux a liberation etendue et procedes de fabrication et d'utilisation associes
EP1562552A1 (fr) * 2002-11-08 2005-08-17 Egalet A/S Compositions de carvedilol a liberation commandee
MXPA05008033A (es) * 2003-01-28 2006-04-28 Collegium Pharmaceutical Inc Composiciones de milnacipran en forma de multiparticulas para administracion oral.
ATE454886T1 (de) * 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
US8802139B2 (en) * 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
CN1938026A (zh) * 2004-03-26 2007-03-28 卫材R&D管理有限公司 控释制剂及其制造方法
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP1830886B1 (fr) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Methode de stabilisation d'un medicament contre la demence
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
US7829000B2 (en) * 2005-02-25 2010-11-09 Hewlett-Packard Development Company, L.P. Core-shell solid freeform fabrication
WO2006110807A1 (fr) * 2005-04-12 2006-10-19 Elan Pharma International Limited Compositions a liberation controlee comportant une celphalosporine pour le traitement d'une infection bacterienne
US20090274759A1 (en) * 2005-06-03 2009-11-05 Egalet A/S Solid pharmaceutical composition with a first fraction of a dispersion medium and a second fraction of a matrix, the latter being at least partially first exposed to gastrointestinal fluids
US20100136106A1 (en) * 2005-06-08 2010-06-03 Gary Liversidge Modified Release Famciclovir Compositions
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
WO2007037259A1 (fr) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. Préparation pour impulsion ayant de meilleures propriétés de désintégration in vivo
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN101453993A (zh) * 2006-04-03 2009-06-10 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008062320A2 (fr) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Formulations à libération prolongée d'un inhibiteur de la pompe à protons
WO2008086804A2 (fr) * 2007-01-16 2008-07-24 Egalet A/S Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
EP2155167A2 (fr) 2007-06-04 2010-02-24 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
EP2214635A1 (fr) * 2007-10-19 2010-08-11 Purdue Research Foundation Formulations solides de composés cristallins
WO2010089132A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Composition à libération immédiate résistant à une maltraitance par prise d'alcool
WO2010143202A1 (fr) * 2009-06-09 2010-12-16 Sun Pharmaceutical Industries Ltd. Composition pharmaceutique
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
CA3018328A1 (fr) 2014-10-31 2016-04-30 Purdue Pharma Methodes et compositions destinees au traitement du trouble de deficit d'attention
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1290661A (fr) * 1960-05-31 1962-04-13 Abbott Lab Méthode d'enrobage de comprimés
US4140756A (en) * 1976-06-10 1979-02-20 Mead Johnson & Company Film-coated matrix core tablet
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
FR2506157A1 (fr) * 1981-05-20 1982-11-26 Lipha Preparation pharmaceutique de " naftidrofuryl " a liberation controlee
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
BR8406921A (pt) * 1983-05-31 1985-06-04 Choong Gook Jang Composicoes secas de compressao,direta para formas de dosagem de liberacao controlada
DE3413608A1 (de) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet

Also Published As

Publication number Publication date
PH23292A (en) 1989-06-30
PT83756A (en) 1986-12-01
EP0224146A3 (en) 1987-09-23
DE3685094D1 (de) 1992-06-04
NZ218297A (en) 1990-03-27
CA1289075C (fr) 1991-09-17
GR862727B (en) 1987-03-19
JPS62120316A (ja) 1987-06-01
EP0224146A2 (fr) 1987-06-03
DK546886A (da) 1987-05-19
ZA868249B (en) 1987-06-24
AU594392B2 (en) 1990-03-08
PT83756B (pt) 1989-06-30
AU6532586A (en) 1987-05-21
US4892742A (en) 1990-01-09
DK546886D0 (da) 1986-11-14
HU200683B (en) 1990-08-28
HUT42321A (en) 1987-07-28
EP0224146B1 (fr) 1992-04-29
CN86107734A (zh) 1987-05-20
IL80643A0 (en) 1987-02-27

Similar Documents

Publication Publication Date Title
MC1782A1 (fr) Preparation pharmaceutique
DK195988D0 (da) Farmaceutisk praeparat indeholdende mikrokapsler
DK89090A (da) Farmaceutisk praeparat
DK481585A (da) Farmaceutisk praeparat indeholdende anthracyclinglycosider
DK705488D0 (da) Farmaceutisk praeparat
DK259186A (da) Nasale farmaceutiske praeparater
DK413987D0 (da) Farmaceutiske praeparater
BE894376A (fr) Preparation pharmaceutique
DK288686D0 (da) Farmaceutiske praeparater
DK652787A (da) Farmaceutiske praeparater
FR2638640B1 (fr) Solution pharmaceutique
DK52086A (da) Farmaceutiske praeparater indeholdende ergotalkaloider
FR2598617B1 (fr) Composition pharmaceutique
DK437686A (da) Anti-rheumatisk farmaceutisk praeparat
DK447887D0 (da) Frysetoerrede farmaceutiske praeparater
DK139388A (da) Farmaceutisk praeparat
DK276288A (da) Farmaceutisk praeparat
IT1200467B (it) Formulazione farmaceutica
DK52186D0 (da) Farmaceutisk praeparat indeholdende indolderivater
DK639787D0 (da) Laegemiddelform indeholdende urapidil
DK138888A (da) Farmaceutisk praeparat
FR2587217B1 (fr) Preparations pharmaceutiques immunomodulantes
DK428287A (da) Nasalt farmaceutisk praeparat
RO91711A2 (fr) Produit medicamenteux reconfortant
SE8504793D0 (sv) Pharmaceutical preparations

Legal Events

Date Code Title Description
YP Annual fee paid